Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5Myeloid 4Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Genitourinary 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Injections 54pembrolizumab 40Carboplatin 20Bevacizumab 19Cyclophosphamide 17toripalimab 14Nivolumab 14Cisplatin 14tislelizumab 13fludarabine 13Specimen Handling 13Paclitaxel 13Interviews as Topic 13Pemetrexed 12Standard of Care 11Practice Guidelines as Topic 11Oxaliplatin 11Fluorouracil 10Cetuximab 10atezolizumab 9Educational Status 9Docetaxel 9Capecitabine 9Leucovorin 8Methods 7Etoposide 7Early Intervention, Educational 7spartalizumab 6olaparib 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Blood Component Removal × Other solid neoplasm × Clear all
NCT04981119 2026-06-02

BASECAMP-1

A2 Biotherapeutics Inc.

Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07137312 2025-12-23

Ex Vivo Expansion (ACT-X)

Mayo Clinic

Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡